JP5247469B2 - タンシノンを用いた炎症性サイトカイン産生の阻害 - Google Patents

タンシノンを用いた炎症性サイトカイン産生の阻害 Download PDF

Info

Publication number
JP5247469B2
JP5247469B2 JP2008550444A JP2008550444A JP5247469B2 JP 5247469 B2 JP5247469 B2 JP 5247469B2 JP 2008550444 A JP2008550444 A JP 2008550444A JP 2008550444 A JP2008550444 A JP 2008550444A JP 5247469 B2 JP5247469 B2 JP 5247469B2
Authority
JP
Japan
Prior art keywords
tanshinone
sepsis
hmgb1
tsniia
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008550444A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009523730A5 (https=
JP2009523730A (ja
Inventor
ワーン、ハイチャオ
チェン、ダージー
サマ、アンドルー・イー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Feinstein Institutes for Medical Research
Original Assignee
Feinstein Institutes for Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Feinstein Institutes for Medical Research filed Critical Feinstein Institutes for Medical Research
Publication of JP2009523730A publication Critical patent/JP2009523730A/ja
Publication of JP2009523730A5 publication Critical patent/JP2009523730A5/ja
Application granted granted Critical
Publication of JP5247469B2 publication Critical patent/JP5247469B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
JP2008550444A 2006-01-13 2007-01-12 タンシノンを用いた炎症性サイトカイン産生の阻害 Expired - Fee Related JP5247469B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75923706P 2006-01-13 2006-01-13
US60/759,237 2006-01-13
PCT/US2007/000945 WO2007084419A2 (en) 2006-01-13 2007-01-12 Inhibition of inflammatory cytokine production with tanshinones

Publications (3)

Publication Number Publication Date
JP2009523730A JP2009523730A (ja) 2009-06-25
JP2009523730A5 JP2009523730A5 (https=) 2013-02-28
JP5247469B2 true JP5247469B2 (ja) 2013-07-24

Family

ID=38288155

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008550444A Expired - Fee Related JP5247469B2 (ja) 2006-01-13 2007-01-12 タンシノンを用いた炎症性サイトカイン産生の阻害

Country Status (7)

Country Link
US (1) US8513227B2 (https=)
EP (1) EP1981489B1 (https=)
JP (1) JP5247469B2 (https=)
CN (1) CN101394860B (https=)
AU (1) AU2007207675B2 (https=)
CA (1) CA2636909A1 (https=)
WO (1) WO2007084419A2 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101327249B (zh) * 2007-06-21 2012-07-18 天津天士力制药股份有限公司 二羟基苯基乳酸在制备治疗败血症的药物中的应用
WO2010088786A1 (zh) * 2009-02-06 2010-08-12 Lin Xiuying 具有cox-2和免疫活性的草药组合物及其制备方法
MX339842B (es) * 2009-12-22 2016-06-14 Avon Prod Inc Composiciones estimuladoras de paxilina y usos cosmeticos de las mismas.
US20110159125A1 (en) 2009-12-29 2011-06-30 Avon Products, Inc. CGRP Compositions and Uses Thereof
ES2413437T3 (es) * 2010-03-10 2013-07-16 Institut Pasteur HMGB1 y anticuerpos anti-HMGB1 en pacientes infectados por VIH especialmente con trastornos neurológicos
WO2012170742A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Treatment and prevention of cancer with hmgb1 antagonists
US9244074B2 (en) * 2011-06-07 2016-01-26 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
CN102949399B (zh) * 2011-08-23 2016-02-24 上海中医药大学附属岳阳中西医结合医院 丹参酮iia在制备抑制角质形成细胞增殖疾病药中的应用
KR101612051B1 (ko) * 2011-12-20 2016-04-27 한국생명공학연구원 단삼 추출물을 포함하는 코로나 바이러스 감염의 예방 또는 치료용 조성물
KR101400900B1 (ko) * 2012-01-26 2014-05-29 한국생명공학연구원 탄시논을 유효성분으로 함유하는 자연살해세포 분화 또는 활성 증진용 조성물
CN102670768A (zh) * 2012-05-15 2012-09-19 宋协勘 一种治疗急性阑尾炎的中药
CN102824349A (zh) * 2012-09-14 2012-12-19 广东省中医院 丹参酮ⅱa在制备治疗银屑病药物中的应用
CN102973575A (zh) * 2012-11-23 2013-03-20 广东省中医院 隐丹参酮在制备治疗银屑病药物中的应用
CN103006549B (zh) * 2012-12-05 2015-04-15 广东宏远集团药业有限公司 采用助溶消泡溶剂制备丹参酮iia磺酸钠制剂的方法
CN103040837A (zh) * 2013-01-13 2013-04-17 广东宏盈科技有限公司 一种眼科外用降眼压药物
GB201312205D0 (en) * 2013-07-08 2013-08-21 Univ Leuven Kath Anticonvulsant activity of dan shen extracting compounds
KR20170006030A (ko) * 2015-07-07 2017-01-17 재단법인 진안홍삼연구소 크립토탄시논을 유효성분으로 포함하는 구강세균 독성에 의한 염증을 예방, 개선 또는 치료하는 조성물
CN105168222A (zh) * 2015-07-23 2015-12-23 南京赋海澳赛医药科技有限公司 组合物及其在抗鼻炎药物中的应用
US11266716B2 (en) 2015-10-22 2022-03-08 The Feinstein Institutes For Medical Research Use of dermcidin in sterile inflammatory conditions
CN108264515B (zh) * 2017-01-04 2021-01-12 中国科学院上海药物研究所 一类苯并[def]咔唑类化合物及其制备方法和应用
CN106924740A (zh) * 2017-03-15 2017-07-07 河南科技大学 一种治疗急性肺损伤的药物组合物
CN106963776A (zh) * 2017-04-26 2017-07-21 上海市疾病预防控制中心 一种化合物在制备以组织蛋白酶k为靶标的疾病药中的应用
CN108785314A (zh) * 2017-05-03 2018-11-13 阎永平 用于治疗和预防酒精性肝病的药物及其组合物
US11026905B2 (en) 2018-04-19 2021-06-08 Tvardi Therapeutics, Inc. STAT3 inhibitors
JP7411315B2 (ja) 2018-04-19 2024-01-11 トゥヴァルディ セラピューティクス，インク． Ｓｔａｔ３阻害剤
CN108685981A (zh) * 2018-07-20 2018-10-23 深圳市博奥生物科技有限公司 一种三七丹参胶囊及其制备方法
CN108837001A (zh) * 2018-07-20 2018-11-20 深圳市博奥生物科技有限公司 一种三七丹参片及其制备方法
AU2019374135A1 (en) * 2018-11-02 2021-06-17 University Of Maryland, Baltimore Inhibitors of Type 3 Secretion System and antibiotic therapy
JP2023520273A (ja) 2020-01-24 2023-05-17 トゥヴァルディ セラピューティクス，インク． 治療化合物、製剤、およびその使用
CN111166754A (zh) * 2020-02-25 2020-05-19 上海市第六人民医院 隐丹参酮在制备防治恶病质骨骼肌萎缩药物中的应用
CN111214467A (zh) * 2020-03-05 2020-06-02 南京巴傲得生物科技有限公司 吲哚布洛芬在抵抗hmgb1促炎活性中的应用
CN113679726B (zh) * 2020-05-18 2025-01-10 上海科技大学 丹参提取物和醌类化合物在抗冠状病毒中的应用
CN111528098A (zh) * 2020-06-10 2020-08-14 甘肃省农业科学院经济作物与啤酒原料研究所（甘肃省农业科学院中药材研究所） 一种当归组培苗生根培养方法
CN115025103A (zh) * 2021-03-04 2022-09-09 上海上药第一生化药业有限公司 丹参酮iia磺酸钠在制备药物中的应用
CN113005130B (zh) * 2021-03-18 2022-07-08 上海辰山植物园 丹参酮ⅱa合酶基因及应用
CA3254067A1 (en) 2022-06-15 2023-12-21 Tvardi Therapeutics, Inc. STAT3 INHIBITOR MEDICINES
CN119950521A (zh) * 2025-01-14 2025-05-09 浙江工业大学 丹参酮i在制备治疗艾滋病的药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0830077B2 (ja) * 1987-04-24 1996-03-27 晟 八木 虚血性疾患治療剤
CN1304723A (zh) 2001-01-16 2001-07-25 中山大学 含二氢呋喃环结构的丹参酮类化合物用于治疗肝性脑病的药物
CN1251718C (zh) * 2003-05-13 2006-04-19 天津红日药业股份有限公司 一种预防、治疗脓毒症的中药复方制剂及其制备方法
JP2007517025A (ja) * 2003-12-30 2007-06-28 エムディー バイオアルファ カンパニー リミテッド 代謝活性を上昇させるタンシノン誘導体を用いる、肥満およびメタボリックシンドロームの治療
KR100725839B1 (ko) * 2005-10-06 2007-12-11 일성신약주식회사 단삼으로부터 분리된 탄시논류의 화합물을 함유하는인지기능 장애의 예방 및 치료용 조성물

Also Published As

Publication number Publication date
AU2007207675B2 (en) 2013-01-31
AU2007207675A1 (en) 2007-07-26
EP1981489A2 (en) 2008-10-22
US20090221542A1 (en) 2009-09-03
CA2636909A1 (en) 2007-07-26
EP1981489B1 (en) 2013-05-01
EP1981489A4 (en) 2010-07-28
JP2009523730A (ja) 2009-06-25
CN101394860A (zh) 2009-03-25
WO2007084419A3 (en) 2008-10-09
WO2007084419A2 (en) 2007-07-26
US8513227B2 (en) 2013-08-20
CN101394860B (zh) 2013-05-29

Similar Documents

Publication Publication Date Title
JP5247469B2 (ja) タンシノンを用いた炎症性サイトカイン産生の阻害
Lee et al. Synergistic effect of natural compounds on the fatty acid-induced autophagy of activated hepatic stellate cells
JP2019112405A (ja) ＧＰＣＲ１９作用剤を有効成分として含有するアレルギー性皮膚疾患の予防又は治療用の組成物｛Ｃｏｍｐｏｓｉｔｉｏｎ ｆｏｒ ｐｒｅｖｅｎｔｉｎｇ ｏｒ ｔｒｅａｔｉｎｇ ａｌｌｅｒｇｉｃ ｄｅｒｍａｔｉｔｉｓ ｃｏｍｐｒｉｓｉｎｇ ＧＰＣＲ１９ ａｇｏｎｉｓｔ ａｓ ａｎ ａｃｔｉｖｅ ｉｎｇｒｅｄｉｅｎｔ｝
US20210283105A1 (en) Novel regimes of fxr agonists
CA2998490A1 (en) Treatment and prevention of neuronal cell loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate
TWI452032B (zh) 治療腎病之醫藥組成物
US20210290610A1 (en) Combination of fxr agonists
JP2022514152A (ja) Ｉｖ型コラーゲン疾患の処置のためのビフェニルスルホンアミド化合物
JP2018524274A (ja) １５−オキソ−ｅｐａまたは１５−オキソ−ｄｇｌａを含む組成物、ならびにその作製及び使用方法
KR101712747B1 (ko) 유파틸린을 유효성분으로 포함하는 피부질환 예방 또는 치료용 조성물
TW202337488A (zh) 白及萃取物治療嗜中性白血球活化失調相關疾病的用途
NO20130284A1 (no) Fremgangsmater og sammensetninger for behandling av cancermetastase
Guo et al. Inhibitory effect of aqueous extract of Scrophularia ningpoensis on β-cell pyroptosis in diabetic mice
CN105273031B (zh) 新颖的三萜化合物及其用途
TW201444561A (zh) 可治療癌症之藥學組合物
CN114159427B (zh) 一种包含安卓幸醇的组合物用于制备抑制肝癌细胞或肝癌干细胞生长的药物的用途
WO2024249509A1 (en) Sparsentan for use in a method of treating iga-mediated diseases
TWI527828B (zh) 新穎的三萜化合物及其用途
CN119732961A (zh) 氨基葡萄糖治疗肝脏疾病和肝脏衰老的用途
Dumitru Medical Treatment of Cystic
CN118542877A (zh) 甘草酸在制备治疗炎症性肠病的药物中的用途
HK1187539A (en) Methods and compositions for treating kidney disorders
WO2017066965A1 (en) Gallic acid-l-leucine conjugate for resolution of inflammation and sepsis
CN108743914A (zh) Vvyp肽或其盐在制备预防或治疗非酒精性脂肪性肝病药物中的应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100112

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110302

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120703

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120907

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120914

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121105

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121112

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121203

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121210

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20121226

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130402

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130409

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20160419

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees